Disease · MONDO_0004974

adrenal gland pheochromocytoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. adrenal gland pheochromocytoma. Diseases, record MONDO_0004974. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004974

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: adrenal gland pheochromocytoma; Open Targets
Open Targets ID: MONDO_0004974; Open Targets
Other names: Intraadrenal paraganglioma, PCC, adrenal gland Chromaffinoma, adrenal gland chromaffin paraganglioma, adrenal gland paraganglioma, adrenal medullary paraganglioma, adrenal medullary pheochromocytoma, adrenal pheochromocytoma, chromaffin paraganglioma of the adrenal gland, pheochromocytoma, pheochromocytoma (adrenal); Open Targets
Disease Ontology: DOID:0050892; Disease Ontology
NCI Thesaurus: C3326; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 21 drugs, from DailyMed and FDA; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IOBENGUANE I 131	CHEMBL1615779	Small molecule	Approval	DailyMed and FDA	6	3	2	Drugs and targets
METYROSINE	CHEMBL1200862	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
PHENOXYBENZAMINE HYDROCHLORIDE	CHEMBL1200787	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
PHENTOLAMINE MESYLATE	CHEMBL1200873	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DOXAZOSIN	CHEMBL707	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PHENOXYBENZAMINE	CHEMBL753	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
AXITINIB	CHEMBL1289926	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ARSENIC TRIOXIDE	CHEMBL5483015	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBIDOPA	CHEMBL1200748	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CATEQUENTINIB HYDROCHLORIDE	CHEMBL5314570	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets48

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor alpha	4	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha	4	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha	4	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
ADRA2A	Adrenergic receptor alpha	4	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha	4	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha	4	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
RET	Proto-oncogene tyrosine-protein kinase receptor Ret	2	Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/5979	Drugs and targets

1 to 10 of 48

See all 48 targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03176693	Preoperative Alpha Blockade for Pheochromocytoma	Phase 3	39	2023-11-20	Pheochromocytoma, Paraganglioma	DOXAZOSIN, PHENOXYBENZAMINE	Its record names the disease	ClinicalTrials.gov
NCT00843037	Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma	Phase 2	25	2024-10-17	Paraganglioma, Pheochromocytoma	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT00458952	Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma	Phase 1/2	24	2016-04-20	Pheochromocytoma, Paraganglioma	IOBENGUANE I 131	Its record names the disease	ClinicalTrials.gov
NCT01967576	Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma	Phase 2	14	2020-08-31	Pheochromocytoma, Paraganglioma	AXITINIB	Its record names the disease	ClinicalTrials.gov
NCT00107289	Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma	Phase 2	200		Neuroblastoma, Pheochromocytoma	ARSENIC TRIOXIDE, IOBENGUANE I 131	Its record names the disease	ClinicalTrials.gov
NCT00028106	131MIBG to Treat Malignant Pheochromocytoma	Phase 2	32		Pheochromocytoma	CARBIDOPA, EMETINE, ISOTRETINOIN, METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT04320589	the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma	Phase 2	30		Pheochromocytoma	DEXMEDETOMIDINE	Its record names the disease	ClinicalTrials.gov
NCT05885386	A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL	Phase 2	20		Pheochromocytoma, Paraganglioma	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT03946527	LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)	Phase 2	10		Paraganglioma, Pheochromocytoma	LANREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT05883085	A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL	Phase 2	10		Pheochromocytoma, Paraganglioma	CATEQUENTINIB HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Phenoxybenzamine vs Doxazosin: Mortality	0 of 19	0 of 20	39	NCT03176693	Trial comparisons
Phenoxybenzamine vs Doxazosin: Participants Admitted to Post-operative Intensive Care Unit (ICU)	2 of 19	1 of 20	39	NCT03176693	Trial comparisons
Phenoxybenzamine vs Doxazosin: deaths from any cause	0 of 19	0 of 20	39	NCT03176693	Trial comparisons
Phenoxybenzamine vs Doxazosin: serious adverse events	0 of 19	0 of 20	39	NCT03176693	Trial comparisons

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27561909	RESULT	1	PubMed
25456922	RESULT	1	PubMed
24939623	RESULT	1	PubMed
20546874	RESULT	1	PubMed
12192533	RESULT	1	PubMed
29099942	DERIVED	1	PubMed
26773712	DERIVED	1	PubMed
26742708	DERIVED	1	PubMed
26040622	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004974

GET https://conductscience.org/api/diseases/v1/MONDO_0004974/drugs?page=2

API reference For AI assistants